CORT · Corcept Therapeutics Incorporated

Current Thesis

Corcept Therapeutics’ thesis is that Lifyorli’s launch sustains revenue growth and relacorilant gains approval for Cushing’s syndrome; the next quarterly report and the 2026-12-17 regulatory decision test those claims. The commercial benchmark is Lifyorli’s $47.6 million of Q2 2026 revenue and the $1.1–1.2 billion full-year revenue guidance announced on 2026-07-29. Corcept’s Q2 release

The September update is a price reset without a verified new operating disclosure. The 2026-09-11 adjusted close was $112.79, with the shares up 36.0% over three months but 8.7% below their $123.57 52-week high. The narrative is maturing — an inference from that retreat after the 2026-07-29 earnings release and the analyst upgrades dated 2026-07-30, rather than evidence that the commercial thesis has failed. Corcept’s release index checked on 2026-09-13 still lists the July results as its latest announcement. Company releases

Bullish and bearish views on Corcept Therapeutics Incorporated

The model's bull view on Corcept Therapeutics Incorporated (CORT), in brief: Launch revenue is measurable. Corcept reported $47.6 million of Lifyorli revenue for Q2 2026, its first quarter of availability. This establishes a commercial starting point; it does not establish a durable growth rate. 2026-07-29 results The existing franchise also grew. Q2… The bear view: Launch durability remains untested. The first-quarter-of-availability figure disclosed on 2026-07-29 supplies too small a sample to support a claim about sustained uptake. Q3 Lifyorli revenue at or below $47.6 million would contradict the sequential-growth leg. Insider selling… Both cases follow in full.

Bull Case

• Launch revenue is measurable. Corcept reported $47.6 million of Lifyorli revenue for Q2 2026, its first quarter of availability. This establishes a commercial starting point; it does not establish a durable growth rate. 2026-07-29 results
• The existing franchise also grew. Q2 2026 Korlym and authorized-generic revenue reached $208.6 million versus $194.4 million in Q2 2025, according to the 2026-07-29 release. Oncology revenue therefore accompanied growth in the endocrinology business that quarter. Company results
• Analysts recognized the earnings reset. Benzinga’s 2026-07-30 reports recorded Piper Sandler’s $165 price target and Canaccord Genuity’s $161 target. These are attributed valuation opinions, not evidence that either market price will be reached.

Bear Case

• Launch durability remains untested. The first-quarter-of-availability figure disclosed on 2026-07-29 supplies too small a sample to support a claim about sustained uptake. Q3 Lifyorli revenue at or below $47.6 million would contradict the sequential-growth leg.
• Insider selling was already executed. Director Kimberly Park’s Form 4 associated with the 2026-08-26 filing showed 26,685 shares sold at a weighted-average $122.5471. This is an observable transaction near the reported high, not evidence of future selling or its motivation; the related Form 144 should not also be counted as pending supply.
• Published valuations remain divided. Wolfe Research’s $50 price target dated 2026-07-27 contrasts with Piper Sandler’s $165 target dated 2026-07-30, as reported by Benzinga. Those dated opinions establish disagreement, without resolving present valuation.

Setup & Price Structure

The measured 2026-09-11 picture combines a positive three-month price change of 36.0% with a 14-day relative strength index (RSI) of 31.1. Neither observation establishes that a base has formed. Current moving-average values and trading-volume evidence are unavailable, so a rising-average support claim or a claim of expanding participation is unsupported.

The $80 late-June breakout reference identified in the 2026-08-30 public coverage remains the structural thesis boundary. It is a historical market reference, not a newly measured moving average. The September 11 close remains above it; a weekly close below $80 would invalidate the continuing breakout thesis.

Catalyst Calendar (next 30 days)

No company-confirmed earnings or regulatory event was identified for 2026-09-13 through 2026-10-13 in the company’s release and event listings checked on 2026-09-13. Investor relations

• 2026-09-30 — Fiscal quarter end. This closes the accounting period for the next launch-revenue comparison; it is not a scheduled results announcement.
• ~2026-11-04, estimated — Q3 results. The estimate follows the 2025-11-04 reporting date and remains unconfirmed. The report tests sequential Lifyorli growth and whether the full-year guidance survives. Prior-year announcement
• 2026-12-17 — Cushing’s regulatory decision. Corcept’s 2026-07-29 update identifies this as the Prescription Drug User Fee Act (PDUFA) target date for the Food and Drug Administration’s decision on resubmitted relacorilant. Approval resolves the regulatory leg; rejection or an extension beyond that date defeats its published timing. Company regulatory update

What Would Change Our Mind

Loss of the late-June breakout structure would end the price thesis: a weekly close below $80 is the observable condition. Independently, Q3 2026 Lifyorli revenue at or below its Q2 $47.6 million, a reduction of the 2026-07-29 full-year revenue guidance, or failure to secure Cushing’s approval by 2026-12-17 would break a fundamental leg.

The case plays out only if sequential launch growth, maintained or increased guidance, and approval by the stated regulatory date occur before the structural invalidation. Evidence conviction is moderate because the July commercial result is measured, while repeat demand and the regulatory outcome remain unresolved.

Correlation Notes

This is a single-name setup: the identified tests concern Corcept’s product revenue and its 2026-12-17 regulatory decision. No paired benchmark-return series accompanies the 2026-09-11 price observations, so a numerical correlation with biotechnology equities or a claim that a sector move explains the advance is unsupported. The insider filing dated 2026-08-26 also cannot establish market-wide crowding or retail participation.